Photo from wikipedia
Several years have passed since olaparib maintenance therapy was approved in patients with platinum sensitive recurrent ovarian cancer (PSROC). We speculated that the response to platinum‐based chemotherapy (PBC) would be… Click to show full abstract
Several years have passed since olaparib maintenance therapy was approved in patients with platinum sensitive recurrent ovarian cancer (PSROC). We speculated that the response to platinum‐based chemotherapy (PBC) would be impaired at the time of recurrence after olaparib maintenance therapy. We conducted a noninterventional retrospective study to clarify this clinical question in a single institution.
Keywords:
platinum;
platinum sensitive;
olaparib maintenance;
maintenance therapy
Journal Title: Journal of Obstetrics and Gynaecology Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Obstetrics and Gynaecology Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!